Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 5/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | APEX1 | P27695 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28261835 | 0.88 | HPGD (1.00) | HTTHPGDALDH1A1KDM4ELMNA | |
| SCHEMBL2208216 | 0.88 | HTT (0.78) | HTTHPGDALDH1A1KDM4ELMNA | |
| SCHEMBL12700344 | 0.86 | HTT (0.76) | HTTHPGDALDH1A1KDM4ELMNA | |
| SCHEMBL16127885 | 0.84 | HTT (0.72) | HTTHPGDALDH1A1KDM4ELMNA | |
| SCHEMBL5575198 | 0.83 | HTT (0.70) | HTTHPGDALDH1A1KDM4ELMNA | |
| SCHEMBL6355044 | 0.83 | HPGD (0.77) | HTTHPGDALDH1A1KDM4ELMNA | |
| SCHEMBL28729043 | 0.83 | HPGD (1.00) | HTTHPGDALDH1A1KDM4ELMNA | |
| SCHEMBL16088714 | 0.82 | HTT (0.68) | HTTHPGDALDH1A1KDM4ELMNA | |
| SCHEMBL4521046 | 0.81 | ALDH1A1 (1.00) | HTTHPGDALDH1A1KDM4ELMNA | |
| SCHEMBL2017132 | 0.81 | ALDH1A1 (0.73) | HTTHPGDALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-13 | — | — | US | claimed |
| EP-1438973-A1 | REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-07-21 | — | — | EP | claimed |
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-13 | — | — | US | disclosed |
| EP-1438973-A1 | REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-07-21 | — | — | EP | disclosed |
| US-6552200-B2 | Antiallergens | MERRELL PHARMACEUTICALS INC. | 2003-04-22 | — | — | US | disclosed |
| US-20010020114-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | MERRELL PHARMACEUTICALS INC. | 2001-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020114-A1 | Novel intermediates useful for the preparation of antihistaminic piperidine derivatives | HRH1, HRH3, HRH4 | HTT 1576/4885HPGD 134/4885ALDH1A1 385/4885 |
| US-20050009812-A1 | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | TFAM, CYP11B2, CYP11B1 | HTT 761/4885HPGD 586/4885ALDH1A1 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.